Cystatin c & Beta 2 Microglobulin in Thalassemic Children.

Status Not yet recruiting

Clinical Trial Summary

Beta thalassemia has many complications on many systems as the renal system.So early detection of renal impairment is required in those children to decrease complications of this nephropathy.

Clinical Trial Description

Thalassemia syndromes are the most common single gene disorders worldwide especially in developing countries. The use of regular and frequent blood transfusions in patients with beta thalassemia major has improved patients' life spans and quality of life, but can lead to chronic iron overload. Many factors contribute to the functional abnormalities found in beta thalassemia patients such as decreased red cell life span, rapid iron turnover, tissue deposition of excess iron and also, specific iron chelators can affect kidneys. The success in management of patients of beta thalassemia has led to chronic hemosiderosis in different organs like liver and heart and long-term complications in other organs like pancreas and kidneys have recently been studied. The evidence of proximal tubular damage has been observed in beta thalassemia patients. Also, low-molecular-weight proteinuria has been found in almost all patients. Unlike other organs, it is unclear whether kidney damage results solely from intravascular haemolysis, chronic transfusion or as a complication of iron chelation therapy. Although the early identification of patients at high risk of renal impairment is of great importance as it may allow specific measures to be taken to delay renal impairment, there are limited studies about renal dysfunction in pediatric thalassemic patients. Thus, in this study we will use different measurements for early detection of renal impairment even if the patients have no symptoms to handle with the disease in its reversible stage before being irreversible. Beside the usual investigations of renal function we will measure cystatin c and beta2 microglobulin as early markers of renal impairment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03881917
Study type	Observational
Source	Assiut University
Contact	Mohamed Naguib Khairy, M.B.B.Ch
Phone	+201091921973
Email	mohamed_ibrahim@med.au.edu.eg
Status	Not yet recruiting
Phase
Start date	November 1, 2019
Completion date	March 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT00106015` - Diamond Blackfan Anemia Registry (DBAR)
Completed	`NCT00059293` - Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
Completed	`NCT00023530` - Blood and Marrow Transplant Clinical Research Network	N/A
Not yet recruiting	`NCT05983536` - The Evaluation of Anti-interference Ability and Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)
Recruiting	`NCT03548766` - Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping	Phase 3
Completed	`NCT00007371` - Hepatitis C in Clinically Discordant Hemophilic Siblings	N/A
Completed	`NCT00000587` - Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection	Phase 2
Completed	`NCT00005682` - Aplastic Anemia Epidemiology: Incidence and Case-control	N/A
Completed	`NCT00005305` - Hepatitis Delta Infections in Hemophiliacs	N/A
Completed	`NCT00005304` - Delta Hepatitis and Liver Disease in Hemophiliacs
Completed	`NCT00005277` - Cooperative Study of The Clinical Course of Sickle Cell Disease	N/A
Completed	`NCT00035763` - Pain in Sickle Cell Epidemiologic Study	N/A
Completed	`NCT00005300` - Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease	N/A
Recruiting	`NCT04600609` - Examining the Experiences of Children With Blood Disorders
Completed	`NCT00005556` - Retention of Bone Marrow Donors in a National Registry	N/A
Completed	`NCT00000597` - Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders	Phase 3
Completed	`NCT03586180` - Medical Clowning: Needs Assessment and Implication for Hospitalized Children With Cancer/Blood Disease
Recruiting	`NCT03848962` - Collection and Distribution of Biospecimens for Novel Research Uses
Terminated	`NCT00486720` - Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)	Phase 2
Completed	`NCT00005518` - Epidemiology and Immunology of Hemophilia A Inhibitors	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Cystatin c and Beta 2 Microglobulin in Thalassemic Children.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms